Drug intelligence / Profile preview

KDM1 siRNA

Development stage
Preclinical
Lead developer
University of Texas Health Science Center at San Antonio
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

KDM1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of lysine-specific demethylase 1 (KDM1, also known as LSD1). KDM1 is an epigenetic enzyme that plays a critical role in histone modification by removing methyl groups from lysine 4 and lysine 9 of histone H3 (H3K4 and H3K9), as well as non-histone proteins like p53. In preclinical research, particularly in gliomas, silencing KDM1 with siRNA has been shown to inhibit cell proliferation and colony formation. Mechanistically, the reduction of KDM1 levels promotes the acetylation of p53 and the subsequent upregulation of its pro-apoptotic target genes, such as p21 and PUMA. Furthermore, KDM1 silencing is associated with increased levels of H3K4-me2 and H3K9-Ac modifications, leading to the induction of apoptosis and the reduction of stemness markers like CD133 and nestin in glioblastoma cells.

Other names
LSD1 siRNALSD-1 siRNALSD 1 siRNAKDM1A siRNAKDM-1A siRNAKDM 1A siRNAlysine-specific demethylase 1 siRNA
02

Targets

KDM1A (LSD1)

Beyond the preview

Go deeper on KDM1 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KDM1 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call